Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: New insight

Journal of Nephrology

Volumn 11, Issue 2, 1998, Pages 70-75

  Bennett, William M ^a   Porter, George A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CAFFEINE; CODEINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ILLICIT DRUG; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANALGESIC NEPHROPATHY; ARTICLE; CHRONIC KIDNEY FAILURE; DRUG ABUSE; HUMAN; PREVALENCE; RISK FACTOR;

EID: 0031967632     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Stewart JH. The analgesic syndrome. In: Stewart JH, ed. Analgesic and NSAID-induced kidney disease. Oxford: Oxford University Press 1993, 58-66.
2. Klag MJ, Whelton PK, Perneger TV. Analgesics and chronic renal disease. Curr Opin Nephrol Hypertens 1996; 5: 236-41.
3. Pommer W, Bronder E, Greiser E. Regular analgesic intake and risk of end-stage renal failure. Am J Nephrol 1989; 9: 403-12.
4. Matousovic K, Elseviers MM, Devecka D. Incidence of analgesic nephropathy among patients undergoing renal replacement therapy in Czech republic and Slovak republic. Nephrol Dial Transplant 1996; 11: 1048-51.
5. Wing AJ, Brunner FP, Geerlings W. Contribution of toxic nephropathies to end-stage renal failure in Europe: A report from the EDTA-ERA Registry. Toxicol Lett 1989; 46: 281-92.
6. Gonwa TA, Hamilton RW, Bruckalew VM. Chronic renal failure and end-stage renal disease in northwest North Carolina: Importance of analgesic-associated nephropathy. Arch Intern Med 1981; 141: 462-5.
7. McAnally JF, Winchester JF, Schreiner GE. Analgesic nephropathy-an uncommon cause of end-stage renal disease. Arch Intern Med 1983; 143: 1897-9.
8. Elseviers MM, Bosteels V, Cambier P, et al. Diagnostic criteria of analgesic nephropathy in patients with end-stage renal failure: results of the Belgian study. Nephrol Dial Transplant 1992; 7: 479-86.
9. Elseviers MM, Waller I, Nenov D, et al. Evlauation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Nephrol Dial Transplant 1995; 10: 808-14.
10. De Broe ME, Elseviers MM, Bengtsson U, et al. Analgesic nephropathy. Nephrol Dial Transplant 1996; 11: 2407-8.
11. Sandler DP, Smith JC, Weinberg CR. Analgesic use and chronic renal disease. N Engl J Med 1989; 320: 1238-43.
12. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin and non-steroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675-9.
13. Elseviers MM, De Schepper A, Corthouts R, et al. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 1995; 48: 1316-23.
14. Segasothy M, Samad SA, Zulfiqar A, Shaariah W, Morad Z, Menon SP. Computed tomography and ultrasonography: A comparative study in the diagnosis of analgesic nephropathy. Nephron 1994; 55: 62-6.
15. Bennett WM, Henrich WL, Stoff JS. The renal effects of non-steroidal anti-inflammatory drugs: Summary and recommendations. Am J Kidney Dis 1996; 28: s56-62.
16. Sandler DP, Burr R, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165-72.
17. Segasothy M, Samad SA, Zulfigar A, Bennet WM. Chronic renal disease and papillary necrosis associated with the long term use of non-steroidal antiinflammatory drugs as a sole or predominant analagesic. Am J Kidney Dis 1994; 24: 17-24.
18. Champion de Crespigny P, Hewitson T, Birchall I, Kincaid-Smith P. Caffeine potentiates the nephrotoxicity of mefenamic acid on the rat renal papilla. Am J Nephrol 1990; 10: 311-5.
19. Calvo-Alen J, De Cos MA, Rodriguez-Valverde V, Escallada R, Florez J, Arias M. Subclinical renal toxicity in rheumatic patients receiving long-term treatment with nonsteroidal anti-inflammatory drugs. J Rheumatol 1994; 21: 1742-7.
20. Dubach UC, Rosner N, Stürmer T. An epidemiologic study of abuse of analgesic drugs-effects of phenacetin and salicylate on mortality and cardiovascular Morbidity. N Engl J Med 1991; 324: 155-60.
21. Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 1995; 48: 1912-9.
22. Rahman A, Segasothy M, Samad SA, Zulfiqar A, Rani M. Analgesic use and chronic renal disease in patients with headache. Headache 1993; 33: 442-5.
23. Elseviers MM, De Broe ME. Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures. Nephrol Dial Transplant 1994; 931: 41-6.
24. Bennett WM, Walker RG, Henry JP, Kincaid-Smith P. Chronic interstitial nephropathy in mice induced by psychosocial stress: Potentiation by caffeine. Nephron 1983; 34: 110-3.
25. Hauser AC, Defler K, Balcke P. Progression of renal insufficiency in analgesic nephropathy: Impact of continuous drug abuse. J Clin Epidemiol 1991; 44: 53-6.
26. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Renal Data System. In USRDS 1996 Annual Report. Bethesda 1996.
27. Elseviers MMA. Epidemiology of analgesic nephrpathy. 1994; 5-10 (abstract).
28. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27: 162-5.
29. De Leeuwe PW. Nonsteroidal anti-inflammatory drugs and hypertension: the risks in perspective. Drugs 1996; 51: 179-87.
30. Klag MK, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-8.
31. Frolich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997; 18: 30-4.
32. Isakson P. Specific cox-2 inhibition: evaluation in animals and man. Nephrology 1997; 3: S27 (Abstract).
33. Wojtulewski JA, Schattenkirchner M, Barcelo P, Le Loet X, Bevis PJR, Bluhmki E. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35: 22-8.